PNKP

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, PNKP Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PNKP data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher PNKP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PNKP expression acts as an unfavorable survival marker.

SCLC, HNSC, and LIHC are the cancer types where PNKP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
SCLCOSMedianII,III,IV0.1370.700<.00136view →
HNSCOSMedianAll0.1560.710.00224view →
LIHCOSMedianAll0.0610.777<.00112view →
LUADDFSMedianIV0.3420.893<.0016view →
Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PNKP–SCLC (OS)

Kaplan–Meier survival curve for PNKP mutant vs wild-type samples in SCLC.

Open the SCLC breakdown →

Exploration